Ruengsaen Atita, Sethasathien Sethawat, Tantipalakorn Charuwan, Charoenkwan Kittipat, Suprasert Prapaporn, Srisomboon Jatupol, Tongsong Theera
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Cancers (Basel). 2025 May 14;17(10):1655. doi: 10.3390/cancers17101655.
: To evaluate treatment outcomes and prognostic factors in patients with ultra-high-risk gestational trophoblastic neoplasia (GTN) compared to those with low-risk and high-risk GTN. : A retrospective review of medical records was conducted for GTN patients treated at Chiang Mai University Hospital, Chiang Mai, Thailand, between January 1999 and December 2019. Overall and risk-specific survival rates were estimated using the Kaplan-Meier method, and prognostic factors were analyzed through univariate and multivariate analyses. : During the study period, 160 patients with GTN were identified, including 98 (61.2%) classified as low-risk, 31 (19.4%) as high-risk, and 31 (19.4%) as ultra-high-risk. One patient in the low-risk group and one in the high-risk group underwent hysterectomy without adjuvant chemotherapy due to spontaneous regression of serum β-hCG (human chorionic gonadotropin). Additionally, one patient with ultra-high-risk GTN died before receiving chemotherapy. Among the 97 low-risk GTN patients, 80 (82.5%) were treated with either single-agent methotrexate or actinomycin D. Among the 30 high-risk GTN patients, 20 (66.7%) received EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine) as first-line chemotherapy, while 24 (80%) of the 30 ultra-high-risk GTN patients received EMA/CO as first-line treatment. Following first-line chemotherapy and/or salvage treatment, patients with ultra-high-risk GTN had significantly worse outcomes compared with those with low- and high-risk GTN, with remission rates of 63.3%, 96.9%, and 80.0%, respectively ( < 0.01). The five-year overall survival rate for patients with ultra-high-risk GTN was significantly lower than that for patients with low- and high-risk GTN (56% vs. 96% and 80%, respectively; < 0.001). On multivariable analysis, significant prognostic factors included antecedent term pregnancy (hazard ratio [HR] = 11.50; 95% confidence interval [CI], 3.56-37.22; < 0.01) and brain metastasis (HR = 4.61; 95% CI, 1.73-12.28; < 0.01). : Ultra-high-risk GTN accounts for only a small proportion of GTN cases but it is associated with poor survival rate and responsible for the majority of GTN-related deaths. Antecedent term pregnancy and brain metastasis were identified as significant prognostic factors.
评估超高危妊娠滋养细胞肿瘤(GTN)患者与低危和高危GTN患者相比的治疗结局及预后因素。
对1999年1月至2019年12月在泰国清迈大学医院接受治疗的GTN患者的病历进行回顾性研究。采用Kaplan-Meier法估计总生存率和风险特异性生存率,并通过单因素和多因素分析来分析预后因素。
在研究期间,共识别出160例GTN患者,其中98例(61.2%)为低危,31例(19.4%)为高危,31例(19.4%)为超高危。低危组和高危组各有1例患者因血清β-人绒毛膜促性腺激素(β-hCG)自发下降而未接受辅助化疗即行子宫切除术。此外,1例超高危GTN患者在接受化疗前死亡。在97例低危GTN患者中,80例(82.5%)接受了单药甲氨蝶呤或放线菌素D治疗。在30例高危GTN患者中,20例(66.7%)接受EMA/CO(依托泊苷、甲氨蝶呤、放线菌素D、环磷酰胺和长春新碱)作为一线化疗,而30例超高危GTN患者中有24例(80%)接受EMA/CO作为一线治疗。在一线化疗和/或挽救性治疗后,超高危GTN患者的结局明显比低危和高危GTN患者差,缓解率分别为63.3%、96.9%和80.0%(P<0.01)。超高危GTN患者的五年总生存率明显低于低危和高危GTN患者(分别为56%、96%和80%;P<0.001)。多因素分析显示,显著的预后因素包括既往足月妊娠(风险比[HR]=11.50;95%置信区间[CI],3.56-37.22;P<0.01)和脑转移(HR=4.61;95%CI,1.73-12.28;P<0.01)。
超高危GTN仅占GTN病例的一小部分,但与低生存率相关,且是大多数GTN相关死亡的原因。既往足月妊娠和脑转移被确定为显著的预后因素。